|Bid||132.93 x 1000|
|Ask||133.19 x 900|
|Day's Range||132.54 - 134.74|
|52 Week Range||113.52 - 174.00|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||12.03|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||170.38|
The company Jazz bought is developing a new treatment for a a nervous system disorder that causes rhythmic shaking.
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down ...
Transaction Adds Worldwide Rights to CX-8998, a Modulator of T-type Calcium Channels, for the Potential Treatment of Essential Tremor Strong Strategic Fit with a Differentiated Mechanism of Action in an ...
Jazz (JAZZ) delivered earnings and revenue surprises of 13.45% and 5.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Total Revenues Increased 7% to $534 Million GAAP Diluted EPS of $4.56 ; Adjusted Diluted EPS of $4.05 Launched Sunosi in Early July in the U.S. Expansion of Defitelio into Japan Following Nippon Shinyaku ...
DUBLIN, Aug. 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the Phase 1 study of its recombinant crisantaspase molecule, JZP-458, met its efficacy and safety objectives. The company plans to initiate a single-arm, pivotal Phase 2/3 study evaluating JZP-458 as a potential treatment option for patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginase products. "Jazz is committed to the ALL patient community, and we are pleased to advance this development program with the goal of bringing a new treatment option to ALL and LBL patients who are hypersensitive to E. coli-derived asparaginase products as soon as possible," said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development of Jazz Pharmaceuticals.
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
How far off is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) from its intrinsic value? Using the most recent financial data...
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DUBLIN , July 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 second quarter financial results on Tuesday, August 6, 2019 , after the close ...
Jazz is paying $3.5 million up front, and another $203 million in contingent payments tied to hitting product development milestones, for an England company's cancer therapy program.
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 9) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Athenex ...
Pan-RAF Program adds an Early Stage, Innovative, Precision Oncology Asset to Jazz Pharmaceuticals' Growing R&D Portfolio Redx to Receive $3.5 Million Upfront, up to $203 Million in Milestone Payments and ...